Jazz Pharmaceuticals Terminates Material Definitive Agreement
Ticker: JAZZ · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-agreement
Related Tickers: JAZZ
TL;DR
Jazz Pharma terminated a big deal, details TBD.
AI Summary
Jazz Pharmaceuticals plc announced on October 10, 2024, the termination of a material definitive agreement. The filing does not specify the other party involved in the agreement or the financial implications of this termination.
Why It Matters
The termination of a material definitive agreement could signal a change in strategic direction or a resolution of a previous commitment for Jazz Pharmaceuticals.
Risk Assessment
Risk Level: medium — The termination of a material definitive agreement can introduce uncertainty regarding future business operations or financial commitments.
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant
- October 10, 2024 (date) — Date of earliest event reported
- 001-33500 (other) — Commission File Number
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the name or details of the material definitive agreement that was terminated.
Who was the other party to this material definitive agreement?
The filing does not disclose the identity of the other party involved in the terminated agreement.
What is the effective date of the termination?
The date of the earliest event reported, which is the termination, is October 10, 2024.
Are there any financial implications or penalties associated with this termination?
The filing does not provide information regarding any financial implications or penalties resulting from the termination.
Does this termination affect any ongoing business operations or partnerships of Jazz Pharmaceuticals?
The filing does not detail the impact of this termination on Jazz Pharmaceuticals' ongoing business operations or partnerships.
Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 13.7 · Accepted 2024-10-16 16:13:42
Key Financial Figures
- $0.0001 — stered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Marke
Filing Documents
- jazz-20241010.htm (8-K) — 26KB
- 0001232524-24-000073.txt ( ) — 153KB
- jazz-20241010.xsd (EX-101.SCH) — 2KB
- jazz-20241010_lab.xml (EX-101.LAB) — 23KB
- jazz-20241010_pre.xml (EX-101.PRE) — 13KB
- jazz-20241010_htm.xml (XML) — 3KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. On January 7, 2015, Jazz Pharmaceuticals, Inc. ("JPI"), a wholly-owned subsidiary of Jazz Pharmaceuticals plc (the "Company"), entered into a Commercial Lease (as amended on January 29, 2018 and July 26, 2018, the " Existing Lease") with The Board of Trustees of the Leland Stanford Junior University ("Landlord") for a building located at 3170 Porter Drive, Palo Alto, California (the "Building"). JPI and Landlord entered into an Agreement for Termination of Lease Amendment and Voluntary Surrender of Premises, which provides for, among other things, amendments of the term for the ExistingLease, which was scheduled to expire on October 14, 2029; which amendment is subject to the condition of Landlord securing a tenant to relet the Building. On October 10, 2024, Landlord notified JPI that it had secured a tenant to relet the Building; accordingly the Existing Lease will terminate effective June 30, 2025. JPI will be obligated to pay Landlord a lease modification payment as a result of the condition precedent being satisfied. On October 11, 2024, JPI entered into a new lease agreement with Hudson Palo Alto Square, LLC, a Delaware limited liability company,for premises located at 3000 El Camino Real, Palo Alto, California (the "Premises"). JPI is expected to occupy the Premises by July 1, 2025. The Company will continue to maintain its U.S. operations in Palo Alto, California, Carlsbad, California and Philadelphia, Pennsylvania.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: October 16, 2024